. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative
responsiveness of generic and speciﬁc quality-of-life instruments.
J Clin Epidemiol 2003;56:52-60.
213. Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire
(CIVIQ-20). Eur J Vasc Endovasc Surg 2010;40:783-9.
214. Kahn SR, M’Lan CE, Lamping DL, Kurz X, Berard A, Abenhaim LA,
et al. Relationship between clinical classiﬁcation of chronic venous
disease and patient-reported quality of life: Results from an international cohort study. J Vasc Surg 2004;39:823-8.
215. Rutherford RB, Moneta GL, Padberg FT Jr, Meissner MH. Outcome
assessment in chronic venous disease. In: Gloviczki P, editor. Handbook of venous disorders: Guidelines of the American Venous Forum.
3rd ed. London: Hodder Arnold; 2009. p. 684-93.
216. Kundu S, Lurie F, Millward SF, Padberg F Jr, Vedantham S, Elias S,
et al. Recommended reporting standards for endovenous ablation for
the treatment of venous insufﬁciency: Joint statement of the American
Venous Forum and the Society of Interventional Radiology. J Vasc
Surg 2007;46:582-9.
217. United States Department of Health and Human Services, Food
and Drug Administration. Guidance for Industry: Chronic cutaneous ulcer and burn woundsddeveloping products for treatment. June 2006. Available at: http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM071324.pdf
218. Romanelli M, Dini V, Barbanera S, Bertone MS. Evaluation of the efﬁcacy and tolerability of a solution containing propyl betaine and polihexanide